期刊文献+

双重抗血小板药物联合中药治疗进展性缺血性脑卒中的临床效果分析

Clinical effect analysis of dual antiplatelet drugs combined with Chinese medicine in the treatment of progressive ischemic stroke
下载PDF
导出
摘要 目的探讨奥扎格雷氨丁三醇、硫酸氢氯吡格雷双重抗血小板联合中药治疗进展性缺血性脑卒中的临床效果。方法选取2022年1月至2023年1月广东三九脑科医院收治的100例未经静脉溶栓及血管内取栓的进展性缺血性脑卒中患者。采用随机数字表法,将患者分为对照组(50例)和试验组(50例)。试验组男23例,女27例;年龄(62.21±10.77)岁。对照组男26例,女24例;年龄(60.52±11.27)岁。对照组采用硫酸氢氯吡格雷+银杏二萜内酯葡胺治疗,试验组在对照组基础上采用奥扎格雷氨丁三醇治疗。两组均连续治疗14 d。比较两组治疗前后美国国立卫生研究院卒中量表(NIHSS)、日常生活能力Barthel指数(BI)评分,治疗效果,治疗期间药物不良反应发生情况。采用独立样本t检验、配对t检验和χ^(2)检验进行统计学分析。结果治疗后,试验组NIHSS评分低于对照组[(16.62±3.07)分比(21.13±3.27)分],BI评分高于对照组[(90.17±7.25)分比(84.41±7.05)分](均P<0.05)。试验组治疗总有效率高于对照组[90.00%(45/50)比50.00%(25/50)](P<0.05)。两组不良反应总发生率比较,差异无统计学意义[4.00%(2/50)比0](P>0.05)。结论奥扎格雷氨丁三醇、硫酸氢氯吡格雷双重抗血小板联合中药治疗进展性缺血性脑卒中效果较好,对临床治疗进展性缺血性脑卒中具有借鉴意义。 Objective To investigate the clinical effect of ozagrel trometamol and clopidogrel bisulfate dual antiplatelet therapy combined with traditional Chinese medicine in the treatment of progressive ischemic stroke.Methods A total of 100 patients with progressive ischemic stroke without intravenous thrombolysis or intravascular thrombolysis were selected from Guangdong Sanjiu Brain Hospital from January 2022 to January 2023.The patients were divided into a control group(50 cases)and an experimental group(50 cases)by the random number table method.There were 23 males and 27 females in the experimental group,aged(62.21±10.77)years.There were 26 males and 24 females in the control group,aged(60.52±11.27)years.The control group was treated with clopidogrel bisulfate+ginkgo diterpene lactone meglumine,and the experimental group was treated with ozagrel trometamol on the basis of the control group.Both groups were treated for 14 days.The scores of National Institutes of Health Stroke Scale(NIHSS)and Barthel index(BI)of daily living ability before and after treatment,treatment effect,and occurrence of adverse drug reactions during treatment were compared between the two groups.Independent sample t test,paired t test,and χ^(2) test were used for statistical analysis.Results After treatment,the NIHSS score of the experimental group was lower than that of the control group[(16.62±3.07)points vs.(21.13±3.27)points],and the BI score of the experimental group was higher than that of the control group[(90.17±7.25)points vs.(84.41±7.05)points](both P<0.05).The total effective rate of the experimental group was higher than that of the control group[90.00%(45/50)vs.50.00%(25/50)](P<0.05).There was no statistically significant difference in the total incidence of adverse reactions between the two groups[4.00%(2/50)vs.0](P>0.05).Conclusion Ozagrel trometamol and clopidogrel bisulfate dual antiplatelet therapy combined with traditional Chinese medicine has a good effect on the treatment of progressive ischemic stroke,which has reference significance for the clinical treatment of progressive ischemic stroke.
作者 蓝志科 廖硕希 胡运新 孙永奇 胡琼力 Lan Zhike;Liao Shuoxi;Hu Yunxin;Sun Yongqi;Hu Qiongli(Department of Neurology,Guangdong Sanjiu Brain Hospital,Guangzhou 510000,China)
出处 《国际医药卫生导报》 2024年第24期4079-4082,共4页 International Medicine and Health Guidance News
基金 广东省医学科学技术研究基金(20211121211256629)。
关键词 进展性缺血性脑卒中 奥扎格雷氨丁三醇 硫酸氢氯吡格雷 抗血小板聚集 Progressive ischemic stroke Ozagrel trometamol Clopidogrel bisulfate Dual antiplatelet therapy
  • 相关文献

参考文献21

二级参考文献251

共引文献257

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部